During and After Treatment
- DARZALEX® is not chemotherapy. DARZALEX® is a monoclonal antibody that works with your immune system. Monoclonal antibodies work by attaching themselves to multiple myeloma cells in your body and directly killing them, and/or signaling your immune system to destroy them
- DARZALEX® finds and attaches to a protein called CD38, which is present on the surface of cells, including high numbers on myeloma cells
The main goal of the study was to measure the length of time patients live without their multiple myeloma getting worse or their passing away from any cause
- Another goal was to measure response rate, which is the percentage of patients who responded to treatment. Talk to your doctor about how response is measured
The majority of patients responded to the following DARZALEX® combination treatments:
DARZALEX® was studied in combination with Revlimid® and dexamethasone (Rd) vs Rd alone in 569 patients who had received a minimum of 1 prior treatment
- 9 out of 10 patients responded to DARZALEX® + Rd vs 7 out of 10 with Rd alone
DARZALEX® was studied in combination with Velcade® and dexamethasone (Vd) vs Vd alone in 498 patients who had received a minimum of 1 prior treatment
- Almost 8 out of 10 patients responded to DARZALEX® + Vd vs almost 6 out of 10 with Vd alone
- DARZALEX® was studied in combination with Revlimid® and dexamethasone (Rd) vs Rd alone in 569 patients who had received a minimum of 1 prior treatment
- DARZALEX® combination treatments reduced patients’ risk of their disease getting worse or their passing away from any cause by more than 60%
Click here if you are a healthcare professional.
Revlimid® is a registered trademark of Celgene Corporation.
Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc.
What to Expect During and After Treatment With DARZALEX®
During the Infusion
Stay mindful of how you feel: It’s important to tell your healthcare provider right away about any discomfort, even if it’s just a cough, runny nose, or throat discomfort, during or after treatment, and especially during the first infusion. These signs and symptoms could mean you are having an infusion reaction to treatment with DARZALEX®.
Infusion reaction symptoms may include:
- runny or stuffy nose
- rash or hives
- throat tightness
- shortness of breath or trouble breathing
- dizziness or lightheadedness (hypotension)
It is important to tell your doctor or nurse about a reaction so that your healthcare team can put an appropriate plan in place.
Infusion reactions are the most common side effect of treatment with DARZALEX® and can be severe. Almost half (48%) of patients in clinical trials had some type of infusion reaction. Infusion reactions can occur with the first infusion (46%), the second infusion (5%), and subsequent infusions (4%).
If you get an infusion reaction, the infusion may be interrupted or stopped. When these symptoms go away, or improve, the infusion can be continued. These reactions are most likely to happen with the first infusion.
If you have had an infusion reaction once, it is less likely to happen with future infusions. Your healthcare provider may decide not to continue treatment with DARZALEX® if you have a strong infusion reaction.
What Can I Expect After Treatment?
You will be given medicines (corticosteroids) by mouth on the first and second day after each DARZALEX® infusion to lower the chance of delayed infusion reactions. If you have a history of breathing problems, you will be given additional medications to help prevent these problems, such as bronchodilators or inhaled corticosteroids.
Be sure to discuss with your healthcare provider when you will receive infusions and to come in for all your infusions and follow-up appointments. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.
Before and after each infusion of DARZALEX®, you will be given medicines that help to reduce the chance of an infusion reaction.
Learn from patients on DARZALEX® and their caregivers about their experiences.
Support at Every Step
Would you like to receive e-mails and other communications from Janssen CarePath that are designed to support you during your treatment journey?